Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631072 · ClinicalTrials.gov registry record · Phase 1
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
A Phase 1 study of Malignant Melanoma, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT00631072: Completed Phase 1 study of Malignant Melanoma, sponsored by Beth Israel Deaconess Medical Center.
NCT00631072 is a Phase 1 study of Malignant Melanoma that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 9 participants, below the 183-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00631072, a Phase 1 study of Malignant Melanoma, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to determine whether we can purify and grow a population of cells from the participants blood (iNKT cells) and then safely give them back to the participant in increased numbers, and whether these cells will then stimulate the bodies own immune response against the cancer. These iNKT cells have been used in laboratory studies and information from these and other research studies suggest that increasing the number of these cells in the blood can stimulate the immune response against tumors.
Conditions Studied
Interventions
- DRUG GM-CSF
- BIOLOGICAL INKT
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-02 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
What the finished NCT00631072 record still lists
NCT00631072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 183-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 2 interventions - of which GM-CSF is the first listed.
NCT00631072 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00631072 about?
NCT00631072 is a clinical study titled "In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer". The purpose of this research study is to determine whether we can purify and grow a population of cells from the participants blood (iNKT cells) and then safely give them back to the participant in increased numbers, and whether these cells will then stimulate the bodies own immune response against ...
What is the current status of trial NCT00631072?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-02. Estimated completion is 2015-04.
What conditions does trial NCT00631072 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT00631072?
The interventions under investigation include: GM-CSF (DRUG), INKT (BIOLOGICAL).
Who is sponsoring clinical trial NCT00631072?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00631072 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00631072's enrollment target sits among peer trials
9 25th of 28 higher than 3 of 28 other Malignant Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia